Getein Biotech Inc
SSE:603387

Watchlist Manager
Getein Biotech Inc Logo
Getein Biotech Inc
SSE:603387
Watchlist
Price: 8.37 CNY 0.48% Market Closed
Market Cap: 4.2B CNY

Wall Street
Price Targets

Price Targets Summary
Getein Biotech Inc

There are no price targets for Getein Biotech Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Getein Biotech Inc Competitors:
Price Targets
1530
3SBio Inc
56% Upside
CRVO
Diffusion Pharmaceuticals Inc
194% Upside
CELC
Celcuity Inc
12% Upside
BVXP
Bioventix PLC
114% Upside
PYXS
Pyxis Oncology Inc
488% Upside
006280
Green Cross Corp
21% Upside
688177
Bio-Thera Solutions Ltd
60% Upside
BMRN
Biomarin Pharmaceutical Inc
55% Upside

Revenue
Forecast

Revenue Estimate
Getein Biotech Inc

For the last 9 years the compound annual growth rate for Getein Biotech Inc's revenue is 17%. The projected CAGR for the next 1 year is 76%.

17%
Past Growth
76%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Getein Biotech Inc

Operating Income forecast
is not available for
Getein Biotech Inc

Net Income
Forecast

Net Income Estimate
Getein Biotech Inc

For the last 9 years the compound annual growth rate for Getein Biotech Inc's net income is 9%. The projected CAGR for the next 1 year is 129%.

9%
Past Growth
129%
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Getein Biotech Inc's stock price target?
Not Available

Getein Biotech Inc doesn't have any price targets made by Wall Street professionals.

What is Getein Biotech Inc's Revenue forecast?
Projected CAGR
76%

For the last 9 years the compound annual growth rate for Getein Biotech Inc's revenue is 17%. The projected CAGR for the next 1 year is 76%.

What is Getein Biotech Inc's Net Income forecast?
Projected CAGR
129%

For the last 9 years the compound annual growth rate for Getein Biotech Inc's net income is 9%. The projected CAGR for the next 1 year is 129%.

Back to Top